Screener
Enliven Therapeutics ELVN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $132,184 | $98,896 |
| Marketable securities | 320,217 | 363,725 |
| Prepaid expenses and other current assets | 10,736 | 12,257 |
| Total current assets | 463,137 | 474,878 |
| Property and equipment, net | 20 | 34 |
| Operating lease right-of-use assets | 290 | 383 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's cash & equivalents?
- Enliven Therapeutics (ELVN) reported cash & equivalents of $132.18M in Q1 2026.
- How has Enliven Therapeutics's cash & equivalents changed year-over-year?
- Enliven Therapeutics's cash & equivalents increased by 30.0% year-over-year, from $101.71M to $132.18M.
- What is the long-term trend for Enliven Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Enliven Therapeutics's cash & equivalents has grown at a 15.7% compound annual growth rate (CAGR), from $47.7M to $98.9M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Enliven Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude